NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
American Association for Cancer Research (AACR) 2019 – STRO-001 Poster
A Phase 1 Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of STRO-001, An Anti-CD74 Antibody Drug Conjugate, In Patients With Advanced B-Cell Malignancies, NCT03424603
Sutro Biopharma to Present at the 18th Annual Needham Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 4, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9 at 4:50 p.m. ET at the Westin Grand Central...
Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments
STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data Expected Mid-2019 STRO-002 Phase 1 Clinical Trial Initiated in Ovarian and Endometrial Cancers SOUTH SAN FRANCISCO, Calif., April 1, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a...
Sutro Biopharma Initiates Phase I Clinical Trial of STRO-002 for the Treatment of Ovarian and Endometrial Cancers
STRO-002, Sutro’s second clinical program, is designed to deliver “toxic payloads” to kill cancer cells Sutro plans to enroll up to 160 patients in open-label, multicenter study SOUTH SAN FRANCISCO, Calif., March 15, 2019 –Sutro Biopharma, Inc. (NASDAQ: STRO) today...
Sutro Biopharma to Present at the Cowen and Company 39th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 5, 2019 –Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, Chief Executive Officer, will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11 at 2:50 p.m. ET at the Marriott...
Sutro Biopharma Expands Leadership Team with Appointment of Vice President of Chemistry
Veteran Pfizer researcher Andreas Maderna, Ph.D., joins the company SOUTH SAN FRANCISCO, Calif., Jan. 29, 2019 –Sutro Biopharma, Inc. (NASDAQ: STRO) today announced the appointment of Andreas Maderna, Ph.D., as vice president of chemistry. Dr. Maderna has extensive...
Sutro to Present at 37th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 3, 2019 –Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, Chief Executive Officer, will present at the 37th Annual J.P. Morgan Healthcare Conference on Thursday, Jan. 10, 2019 at 11:30 a.m. PT / 2:30 p.m. ET at...
Non-Confidential Corporate Presentation – JPM 2019
Sutro Achieves $10 Million Milestone Payment from Celgene
Sutro develops successful spray drying technology marking a major advancement in commercial-scale manufacturing capabilities SOUTH SAN FRANCISCO, Calif., Dec. 19, 2018 -- Sutro Biopharma, Inc. (NASDAQ: STRO), today announced that the company earned $10 million in a...
Sutro to Participate in the 30th Annual Piper Jaffray Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2018 -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...